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Background: The +T294C polymorphism in PPARδ represents a functional SNP affecting transcriptional activity of the 
PPARδ gene. To address whether this polymorphism is associated with the risk for coronary heart disease and/or 
plasma lipid levels in women, we studied a group of 967 female patients with hyperlipidaemia in the presence  (n=453) 
or absence (n=514) of coronary heart disease.  
Methods: 967 female patients with or without coronary heart disease were genotyped using mutagenically separated 
polymerase chain reaction (MS-PCR). Statistical analysis was performed according to genotype with parameters of 
lipid metabolism as dependant variables.  
Results: A highly significant association between the rare C allele and lower plasma HDL concentrations was found in 
female subjects. The effect remained significant after correcting for multiparametric testing according to Bonferoni and 
was seen only in subjects with a BMI below the median. Moreover, a significant association of the C-allele with 
coronary heart disease and BMI was obtained. Regarding the entire group, trends towards higher VLDL and LDL 
levels were observed.  
Conclusions: Our data show for the first time that the PPARδ +T294C polymorphism is associated with lipid levels and 
coronary heart disease in women. However, the molecular mechanism of action remains to be elucidated. 
1.  Background 
Peroxisome Proliferator-activated receptors (PPAR) 
are ligand activated transcription factors involved in the 
regulation of energy balance [1]. Three closely related 
members belong to the PPAR subgroup termed PPARα, 
PPARγ, and PPARδ. While PPARα is mainly expressed in 
liver, muscle, kidney and heart, PPARγ is most abundant 
in adipocytes, intestinal cells and macrophages and 
PPARδ is expressed in many tissues [2-4]. Each subgroup 
is activated by a certain variety of fatty acids and their 
derivatives and by specific pharmacological ligands. 
After forming obligate heterodimers with the retinoid X 
receptor, PPARs bind to specific elements in the promoter 
region of target genes called PPAR response elements 
(PRE), thereby altering metabolism by activating a 
network of downstream genes. Whereas PPARα 
promotes ß-oxidation, PPARγ has been attributed the role 
of a master regulator of adipocyte differentiation. In 
contrast, the precise function of PPARδ is less well 
established. Treatment of obese rhesus monkeys with the 
synthetic PPARδ agonist GW501516 resulted in an 
increase of high-density lipoprotein cholesterol (HDL) 
levels and a decrease of plasma triglycerides [5]. In 
addition, db/db mice expressing an activated form of 
PPARδ are resistant to obesity and hyperlipidaemia 
when overfed and muscle-specific overexpression of the 
receptor increased the number of muscle fibers with high 
oxidative metabolic capability [6,7]. Taken together, these 
results imply an important role of PPARδ in lipid 
metabolism and thermogenesis.  
The +294T/C polymorphism in exon 4 of the PPAR 
δ gene was initially described by Skogsberg et al [8]. It 
was shown that the polymorphism influenced binding of 
Sp-1 resulting in higher transcriptional activity for the 
rare C allele than the common T allele. In a group of 543 
healthy, middle-aged men the C genotype was associated 
with elevated levels of low-density lipoprotein (LDL) 
cholesterol and apolipoprotein B (Apo B). In 580 male 
subjects with hyperlipidaemia recruited from the West of 
Scotland Coronary Prevention Study (WOSCOPS) 
carriers of the C allele had significantly lower HDL 
plasma concentrations and homozygotes had a tendency 
towards a higher risk for coronary heart disease (CHD) 
[9]. In order to investigate whether these associations are 
also valid in women, we studied the +294T/C 
polymorphism in a group of 967 female patients with 
mixed hyperlipidaemia in the presence or absence of 
coronary heart disease. 
2.  Methods 
Patients 
All subjects were recruited between 1999 and 2004 
from patients who attended the obesity and cardiology 
outpatient clinics of the University of Hamburg Hospital. 
Table 1 summarizes the patient characteristics. The vast 
majority were Caucasians and to our knowledge there 
were no related subjects among the samples. Informed 
consent was obtained from all patients and the study was 
approved by the local ethics commission. After 
measuring lipid values at their first visit to the clinic any 
lipid lowering medication was discontinued unless in 
patients presented with unstable angina or recent 
myocardial infarction. Only patients were included in 
whom a cessation of medication could be performed. All 
patients received dietary advice in a 30-60 minute 
discussion with a dietary assistant in which they were 
instructed to reduce their daily fat intake to a maximum Int. J. Med. Sci. 2006, 3  109
of 40-55 g. Patient compliance was supervised by handing 
out a nutritional diary which was submitted at each of 
the further visits to the clinic. After 6 weeks the patients 
attended the clinic again and it is the lipid values and 
biometric data obtained at this visit which were used for 
statistical analysis in this study. The presence of chd was 
assessed by medical records and/or self-reported 
questionnaire and each case was validated by cardiac 
ultrasound and/or electrocardiographic examinations or 
by coronary angiography. 
Table 1: Patient characteristics. 
 CHD-  CHD+  p-value 
n 514  453   
Age (years)  42.2  44.1   
BMI (kg/m²)  25.9±6  28.8±7.4  0.01 
Cholesterol (mg/dl)  269.6±65.7  285.3±131.3  ns 
LDL 172.9±59.1  195.2±76.3  0.02 
HDL 56.5±18.4  43.7±12  <0.001 
VLDL  28.5±14.2   29.3±15.3   0.015 
Triglycerides (mg/dl)  220.8±119.9  237.9±112  0.001 
Apo B (mg/dl)  131.7±28.2  189±29.9  0.005 
Apo A1 (mg/dl)  162.8±5.8  128±34.1  0.03 
Lp(a) (mg/dl)  24.1±8.7  37.4±9.6  ns 
Biochemical measurements 
Plasma total cholesterol and triglycerides were 
determined using GPO-PAP and CHOD-PAP kits, 
respectively, from Boehringer Mannheim (Mannheim, 
Germany). HDL was measured following precipitation of 
apoB containing lipoproteins with phosphotungstate 
(Boehringer Mannheim). Apoliprotein AI (Apo AI) and 
Apo B were measured using the Beckmann Array 360 
(Beckmann Instruments). 
Genotyping 
DNA was extracted from white blood cells using 
standard methods. A mutagenically separated 
polymerase chain reaction (MS-PCR) was developed to 
separate wildtype (wt) and mutated alleles as described 
[10]. The longer primer for detection of the wt allele was 
5’-TTC AAG CCC TGA TGA TAA GGT CTT TGG CAT 
TAG ATG CTG TTT TGT TTT-3.’ The shorter primer was 
5’-CTT TTG GCA TTA GAT GCT GTT TTG TCC TG-3.’ 
As reverse primer we used 5’-CTT CCT CCT GTG GCT 
GCT C-3.’ PCR condition were: 96°C for an initial 5 
minutes (min.) followed by 96°C 1 min., 65°C 1 min., 72°C 
1 min. for 43 cycles and final extension at 72° for 10 min. 
MS-PCR created two fragment of divergent length which 
were detected by silver staining on polyacrylamid gel.  
Statistical Analysis 
Allele frequencies were determined by gene 
counting and compared using the א² test. The data was 
analysed using SPSS 12.0 software. The association 
between the +294T/C polymorphism and serum lipids, 
coronary heart disease, and body mass index (BMI) was 
calculated using the Student’s t-test analysis with 
genotype as the group variable and total cholesterol, 
triglycerides, vldl-, ldl-, hdl cholesterol and lipoprotein (a) 
as dependent variables. Bonferoni’s correction for 
multiple testing was performed by multiplying the p 
value with the number of tests where appropriate. To 
prevent generating subgroups too small for analysis, 
allelic variants were dichotomized in TT and TC/CC. A 
p-value of 0.05 or lower was considered statistically 
significant. Data were adjusted for age, smoking, and 
BMI where appropriate. 
3.  Results 
The frequency of the C-allele was 0.24 and the 
genotypes were distributed according to the Hardy 
Weinberg Equilibrium. Overall the C allele frequency was 
higher in patients with coronary heart disease than in 
those without, but this difference was not statistically 
significant. The plasma lipid values according to 
+294T/C genotype are shown in table 2. There was a 
trend towards higher LDL in the group of C allele carriers 
but with this was not statistically significant. However 
patients carrying the C allele presented a significantly 
lower VLDL. In the entire group no significant interaction 
between genotype and coronary heart disease could be 
detected. Eliminating patients with diabetes mellitus or 
triglycerides higher than 1.000 mg/dl which likely 
represent cases of secondary hyperlipidaemia did not 
alter our findings. A possible gene-to-gene interaction 
between PPARδ +294T/C and Apolipoprotein E (ApoE) 
was analysed for each ApoE genotype separately but did 
not present statistically significant results (data not 
shown).  
HDL plasma levels are inversely related to BMI. 
Thus potential associations of PPARδ with HDL-C levels 
could be masked by the profound effect of overweight on 
HDL-C in the patients with high BMI. To establish 
whether differences regarding the BMI affected our data 
the allele frequencies in patients with a BMI above the 
median were compared with those below the median. 
Patient characteristics for each group are presented in 
table 3. Within the group of leaner patients there was a 
significantly higher incidence of coronary heart disease 
for carriers of at least one C allele (p=0.033) (table 4). 
Among those with a BMI below 24.6 carriers of the rare C 
allele had a significantly higher BMI than T allele 
homocygotes (p=0.023). Whereas no effect was seen on 
total cholesterol and LDL, C allele carriers had a lower 
HDL than T homozygotes and this difference was 
statistically highly significant (p=0.007) (figure 1). Further 
division of patients created subgroups to small for 
statistical analysis.  
Table 2: Plasma lipid values according to genotype. 
 TT  CT/CC  p-value 
n 599  368  ns 
Age (years)  43.4±14.8  42.8±15.9  ns 
BMI (kg/m²)  24.9±6  24.1±6.3  ns 
Cholesterol (mg/dl)  266±63.3    267±80.3  ns 
LDL 172±73.2  182±55.5  ns 
HDL 53±18.7  53±17.8  ns 
VLDL 27±15.4  24±12.5  0.033 
Triglycerides (mg/dl)  147±137.3 127±169.3  ns 
Apo B (mg/dl)  129±35.6  131±26.3  ns 
Apo A1 (mg/dl)  138±26.9  172±35.8  ns 
Lp(a) (mg/dl)  11±9.7  6±12.1  ns 
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Table 3: Clinical characteristics of patients above and below 
median BMI (24.6) 
  Below median BMI  Above median 
BMI 
n total 
n with chd 
n without chd 
561 
247 
314 
406 
206 
200 
Age (years)  41.3±16.3  45.5±14.4 
BMI (kg/m²)  22.6±1.5  33.8±4.2 
Cholesterol (mg/dl)  268±13.9  279.2±44.8 
LDL 184±21.1  180.3±52.6 
HDL 60±12.5  38.8±19.2 
VLDL 22.5±4.1  38.1±14.9 
Triglycerides (mg/dl)  116.4±180.9  384±214.4 
Apo B (mg/dl)  100.1±22.6  239.2±31.3 
Apo A1 (mg/dl)  159±26.8  129.3±44.5 
Lp(a) (mg/dl)  6.1±9.2  64.2±14.3 
Table 4: Patients below median BMI (24.6 kg/m²) according to 
genotype 
 TT  CT/CC  CT  CC  p-value* 
n 342  219  211  8   
chd present  81  71  70  1  0.033 
BMI (kg/m²)  22.1±1.5  22.9±1.3  22.9±1.1  23.1±1.1  0.023 
Cholesterol 
(mg/dl) 
270.5±51.2 266.2±89.4 266.4±93.2  262±64.5  ns 
LDL 183±46.8  189±54.8  194±53.9  174.6±62.5  ns 
HDL 65.5±20.6  53.5±16  54±16  58.2±17.8  0.004 
VLDL 22±13.2  23±8.8  23.4±8.8  19.2±4.8  ns 
Triglycerides 
(mg/dl) 
112±115.4 118±181.6 118.9±84.5 96.4±23.8  ns 
Apo B (mg/dl)  100±22.6 103.3±21.1 103±11.1 111.5±9.8  ns 
Apo A1 
(mg/dl) 
159±26.8 161±24.3  161.1±13.3  159±22.1  ns 
Lp(a) (mg/dl)  6±4.2  12±14.1  12.1±8.8  10.7±3.4  ns 
*referring to TT vs CT/TT; Student’s t-test.  
Figure 1: HDL-levels according to genotype above and below 
median BMI. Boxes represent T allele homocygotes (TT) or C 
allele carriers (C).  
 
4.  Discussion and Conclusions 
To address the question whether the +T294C 
polymorphism in PPARδ is associated with the risk for 
coronary heart disease and/or plasma lipid levels in 
women, we investigated this genetic variant in a group of 
female patients with hyperlipidaemia in the presence or 
absence of coronary heart disease. As previously 
observed in men by Skogsberg et al. [9], we found a 
highly significant association between the rare C allele 
and lower plasma HDL concentrations in female subjects. 
The effect remained significant after correcting for 
multiparametric testing according to Bonferoni and was 
seen only in subjects with a BMI below the median. In 
addition, the non-corrected data revealed a significant 
association of the C-allele with coronary heart disease. 
Regarding the entire group, trends towards higher VLDL 
and LDL levels were observed. Results in support of our 
f i n d i n g s  w e r e  a l s o  o b t a i n e d  b y  C h e n  e t  a l .  [ 1 1 ] ,  w h o  
studied 4 PPARδ haplotypes and found that effects on 
plasma lipids and coronary lesions were primarily due to 
the influence of the +T294C SNP. The C allele frequency 
of 0.24 in our high risk patient group was similar as the 
frequency of 0.21 reported by Chen et al. in their study 
for chd patients derived from the lipoprotein coronary 
atherosclerosis study. Conversely, Skogsberg et al. found 
a somewhat lower C allele frequency in their study with 
healthy young men from Sweden [9].  
Treatment of obese rhesus monkeys with GW 
501516, a selective PPARδ agonist, led to a significant 
improvement of metabolic traits characterized by a rise of 
HDL and lowering of LDL, triglycerides, and insulin [5]. 
In addition, transgenic expression of an activated PPARδ 
in mice conferred resistance to obesity and 
hyperlipidaemia [6]. Considering that the C allele is 
linked to a higher basal transcriptional activity, it is 
currently unclear why this allele is associated with lower 
HDL and a trend towards higher LDL levels in humans. 
Of note both animal studies used obese models to 
investigate the effect of an activated PPARδ. In an obese 
state the activities of numerous interacting genes are 
altered which may influence the effect of PPARδ on 
metabolism. In our data and in the study by Skogsberg et 
al., the effect of the C allele on lipid levels increased if 
over-weight individuals were excluded from the study. 
Since Skogsberg et al. and also Chen et al. [8, 11] 
have shown that the PPARδ T+294C SNP is associated 
with elevated plasma LDL cholesterol and apoB levels in 
men and we show in this work that similar associations 
are operating in women, we also looked for a potential 
gene-to-gene interaction between PPARδ and apoE. 
Allelic variation in apoE is known to be associated 
consistently with plasma concentrations of cholesterol, 
LDL cholesterol and apoB in men and women (reviewed 
in ref. [12]). However, our data do not provide evidence 
for a gene-to-gene interaction between both genes and 
exclude the possibility that the observed associations are 
due to apoE rather than PPARδ in our study.  
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